Home
About
Capabilities
R&D
Investors
News
Careers
简
繁
Home
About
Capabilities
R & D
Investors
News
Careers
Press Release
Press Release
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
Jun 24, 2026
Mabwell Receives IND Clearance from NMPA for 9MW5211 for multiple sclerosis
➞
Jun 23, 2026
Mabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311
➞
Jun 18, 2026
Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
➞
Jun 16, 2026
Mabwell's Subsidiary Myvision Enters Strategic Cooperation with VivaVision
➞
Jun 15, 2026
EHA 2026 | Mabwell Presents Latest Clinical Results of Novel Anti-TMPRSS6 Monoclonal Antibody 9MW3011
➞
Jun 12, 2026
Mabwell’s LILRB4/CD3 targeting TCE Bispecific Antibody 6MW5311 Receives FDA Clearance for Clinical Trial Application
➞
Jun 05, 2026
Mabwell’s 9MW5211 Receives IND Clearance from NMPA for Inflammatory Bowel Disease
➞
Jun 04, 2026
Mabwell’s Subsidiary Myvision Appears at Retina China 2026
➞
Jun 03, 2026
Highlights in Oral Presentation of Mabwell's 9MW2821 at 2026 ASCO
➞
Jun 02, 2026
Press Conference on Early Diagnosis and Clinical Translation of Parkinson’s Disease & SST001 Clinical Trial Initiation Meeting Successfully Held
➞
1
2
3
4
Next